Table 2:

Common Anticancer Drugs and Regimens for Treatment of mCRC

Note.—Commonly used combination regimens include FOLFOX (5-FU, leucovorin, and oxaliplatin [± bevacizumab or panitumumab]); FOLFIRI (5-FU, leucovorin, and irinotecan [± bevacizumab, panitumumab, or cetuximab]); and CAPEOX (capecitabine, leucovorin, and oxaliplatin [± bevacizumab]). CCT = conventional chemotherapeutic, mAb = monoclonal antibody, TKI = thyrosine kinase inhibitor.

^*Manufacturers are as follows: Efudex: Valeant Pharmaceuticals, Bridgewater, NJ; Carac: Naman Pharma, Mumbai, India; Adrucil: TEVA Pharmaceutical, Petah Tikva, Israel; Wellcovorin: Bedford Laboratories, Bedford, Ohio; Xeloda: Hoffmann-LaRoche, Basel, Switzerland; Camptosar and Campto: Pfizer, New York, NY; Eloxatin: Sanofi Aventis, Bridgewater, NJ; Avastin: Genentech, South San Francisco, Calif; Erbitux: Bristol-Myers Squibb, New York, NY; Vectibix: Amgen, Deerfield, Ill; Zaltrap: Sanofi Aventis; Stivarga: Bayer.

^†FDA cannot verify year of approval before 1984.